e4e6 Consulting

Sometimes, our team is where it is not expected to be ... 😀

The nomination of Robert F. Kennedy Jr. as U.S. Secretary of Health could reshape the global biotech landscape. While aimed at making medicines more affordable, his policies could drastically impact innovation and investment in the sector, particularly for European players. In the context, it is time to act: for entrepreneurs, for investors, for governments, for Europe! If we do not want the biotech graveyard keeping on filling up, let's hear the wake up call!! Read the full article and feel free to come back with comments. #BiotechEurope #InnovationAtRisk #KennedyEffect #BiotechCrisis #PharmaUnderPressure https://lnkd.in/eHmQr78B

Les Echos ce matin font le point sur les dernières réflexions du gouvernement en matière de financement de l’innovation. Le rabotage du CIR devrait apporter 430 millions d’économies qui financeront le prolongement de du crédit d’impôt innovation et le statut de Jeune entreprise innovante (JEI) Le compromis consiste principalement + A sortir les activités liées aux brevets ou à la veille technologique du champ des dépenses éligibles au CIR ❎ Pourquoi pas? cette mesure risque d’impacter plus les grandes entreprises, qui consacrent davantage de ressources aux brevets et à la veille que les start-up. ❌ Cela pourrait-il aussi décourager la protection des innovations et, à terme, réduire l'avantage compétitif des entreprises françaises à l'international, au moins pour ce qui concerne les start up. + A supprimer le dispositif « jeunes docteurs » ❌ A l’heure où le gouvernement veut augmenter le nombre de Docteurs*, ou est la cohérence (Ah pardon, c'est le fameux "en même temps") ❌ Ce dispositif est un moyen d’inciter les entreprises à embaucher des docteurs, en valorisant leur expertise en recherche. Alors que beaucoup de jeunes docteurs "se cherchent" et où les entreprises ont besoin de leur enthousiasme et de leurs compétences, cela semble être une approche à la Gribouille + A baisser le taux applicable aux dépenses de fonctionnement de 43 % à 40 %. ❌ Cette mesure augmente le "reste à charge pour les entreprises", ce qui pourrait particulièrement affecter les startups, pour lesquelles chaque réduction de coût est vitale. En Biotech et Medtech, l'impact peut être colossal voire létal. Sérieux coups de rabot du CIR contre prolongement du CII et du statu JEI: Marché de dupe ou bon compromis? Qu'en pensez vous? * Les Echos, le 8 Novembre 2024 #CIR #Biotech #medtech #innovation #JEI https://lnkd.in/esgs7jxU

📈 As international trade enters uncharted waters, your international expansion strategy shouldn’t rely on guesswork. At e4e6 Consulting we provide SMEs and start-ups with deep expertise to help you be better prepared or strengthen your internationalization strategy. We also can help you with concrete hands-on operational support for international expansion. We give your business the resilience it needs to thrive globally—even amidst uncertainty. Want to make your international strategy stronger than political shifts? Let’s chat. #ResilientGrowth #InternationalTrade #ExportStrategy #GlobalExpansion #Healthcare #SMEs #TradeUncertainty #startups https://lnkd.in/esbuHiqS

e4e6 Consulting is a (proud) member of France Biotech and is always happy to answer questions and support Biotech, Medtech and Digital Health companies with corporate development questions from internationalisation to transaction support. Feel free to reach out. 😊 #Biotech #Medtech #DigitalHealth #esante #internationalisation

As boundaries blur between business and politics, CEOs must navigate not only market trends but also shifting global power dynamics. Understanding geopolitical dynamics is no longer a luxury for CEOs: it is a must. Today, November 4th, 2024, we are on the eve of one of the most pivotal US elections in recent history. The world is holding its breath! It is more than a political event, it is (also) a crossroads for international business. Both candidates will bring policies that could reshape global markets. 🔗 Read the full article to learn why it matters so much for CEOs to master geopolitics when operating and expanding internationally. #Geopolitics #GlobalStrategy #USElection2024 #InternationalBusiness #CorporateLeadership https://lnkd.in/ewzfMbBx

Today, Les Echos are highlithing the EU-Mercosur Deal Progress or Pitfall? 🌍 Brussels is racing to seal the EU-Mercosur trade deal by year-end, but at what cost? Europe claims to champion high environmental standards, yet the deal risks opening doors to goods produced with looser regulations. Is this really green, or just greenwashing? 💼 The deal will reduced tariffs on European goods and increased export quotas offering significant Business opportunities for EU companies. 🚨 Meanwhile, EU local farmers and producers could be undercut by cheaper imports. A €1 billion support fund? It won’t kick in until 2028 (if competition issues are even “proven.”) and actually does not cast a shade of confidence of the deal. Is this deal a smart play for a sustainable, resilient Europe or are we looking at a shortcut with a long-term cost? What do you think? #TradeDeals #EUMercosur #SustainableTrade #GlobalStrategy #Mercosur

Sanofi is (partly) divesting Doliprane: Is it an issue for France or for Sanofi? Sanofi has high risk R&D strategy? Well, investors will reward or punish depending on the outcome Bpifrance is investing € 150 Mio in Opella: This should raise concerns!! Read Eric Rambeaux, our CEO, thoughts on the topic and feel free to share your views. #innovation #bpifrance #doliprane #sanofi #biotech #Pharma #LifeSciences #HealthTech https://lnkd.in/eArPg5TU

e4e6 Consulting had the pleasure of attending France Biotech New Members Event earlier this week. It was a great opportunity to connect with others in the biotech and life sciences sector. We’re excited to be part of the France BioTech community and look forward to collaborating on the challenges and innovations ahead. #Biotech #FranceBioTech #e4e6Consulting #Networking #medtech #esanté #digitalhealth

Global trade is back, but is Europe ready for the new normal? Les Echos points out that while global trade is rebounding, Europe lags behind, particularly in some sectors like automotive and chemicals. The article hints at external factors like geopolitical tensions and competition from Asia, but isn' there a crucial challenge it seems to overlooks?: Europe’s adaptability in the face of rapid global changes. With decarbonization, digital transformation, and reshuffling supply chains, is Europe prepared for the emerging trade ecosystem? If Europe continues to depend on legacy industries and be somehow naive with US and China giant? doesn't it risk missing out on the very sectors that are driving future global growth?? Happy to read opinions on this! #GlobalTrade #TradeChallenges #SupplyChains #ExportStrategy #FutureOfTrade